The New Ferring Oncology Division
In the US, 80,000 people are diagnosed with bladder cancer annually1.
Ferring is building its US Oncology team in preparation to commercialize nadofaragene firadenovec (rAd-IFN/Syn3), a novel gene-mediated therapy in Phase 3 development to potentially treat high-grade non-muscle invasive bladder cancer (NMIBC) patients, who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The US FDA has granted Fast Track and Breakthrough Therapy designation for nadofaragene firadenovec.
Ferring Oncology in the News
A Humanity Driven Focus (PharmaVOICE, August 01, 2019)
Ferring Pharmaceuticals Appoints New Cancer Division Lead (PMLiVE, January 29, 2019)
Ferring Makes Foray Into Gene Therapy With FKD Pact (Scrip, May 03, 2018)
Ferring Commits to US Oncology and Cutting-Edge Research (The PharmaLetter, May 03, 2018)
Ferring Gains Option for Bladder Cancer Gene Therapy (BioCentury, May 03, 2018)
Ferring Gains Option to FKD’s Phase III Bladder Cancer Gene Therapy Candidate (GEN, May 03, 2018)
Ferring Oncology News Releases
1. NIH, Cancer Stat Facts: Bladder Cancer, https://seer.cancer.gov/statfacts/html/urinb.html accessed 6/20/19